← Innovent Biologics overview

Innovent Biologics vs Amgen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Innovent Biologics Inc (1801.HK)

Q3 2026
▲3▼1

Innovent advances pipeline, licensing, and revenue; risks persist

  • Pipeline and licensing progress Innovent started Phase 3 trials for a fast-tracked myeloma antibody, gained China rights to Verzenio and Vanflyta, licensed IBI355 to Spero for up to $1.1B, and filed the world's first weekly oral GLP-1.

    These pipeline and licensing moves are key new developments that can drive future growth and investor optimism.

  • Strong revenue growth First-half product revenue rose over 55% to 8.2 billion yuan, showing strong commercial execution and underlying business momentum.

    Revenue growth is a fundamental driver of stock performance and reflects the company's financial health.

  • Sector re-rating on licensing activity A sector re-rating driven by record Chinese licensing activity boosted valuations across the biotech space, lifting Innovent's shares.

    This external factor improved sentiment and valuation multiples for the entire sector, including Innovent.

  • Risks from trial and deal flow Sector rallies can cool if deal flow slows, and pipeline bets like IBI3003 and IBI3042 depend on costly, uncertain late-stage trials and regulatory outcomes.

    These risks could negatively impact the stock if they materialize, providing a balanced view.

August 2026
▲4

Innovent adds Daiichi deal and weekly GLP-1 filing as sector re-rates

  • World-first weekly oral GLP-1 enters clinic Innovent's IBI3042 became the first small-molecule weekly oral GLP-1 to reach clinical stage, with China's drug regulator accepting the filing. A once-weekly pill would be easier for patients than injections, so success could open a large obesity and diabetes market and lift long-term sales hopes.

    New pipeline milestone that expands Innovent's biggest growth opportunity beyond current products.

  • Wins China rights to Daiichi Sankyo's Vanflyta Innovent secured exclusive China commercialization rights for Vanflyta, a leukemia drug approved in June 2026, while Daiichi Sankyo handles development and supply. This adds a near-term oncology product to sell through Innovent's existing hospital network, lifting revenue without big new research spending.

    A concrete new commercial deal that adds revenue and shows Innovent's partnering strength.

  • First-half product revenue up over 55% Innovent's first-half product revenue topped 8.2 billion yuan, up more than 55% year on year, reported alongside strong results from BeiGene and RemeGen. Faster product sales show its medicines are being adopted widely, which supports profit growth and gives the stock a fundamental reason to rise.

    Actual reported sales growth is the core evidence behind the share price move.

  • Sector re-rating on record licensing and Moderna data Chinese drug licensing deals hit about $99.7 billion in the first half, roughly double all of 2024, and Moderna's cancer vaccine success lifted biotech shares globally. Innovent landed billion-dollar overseas deals, so investors are paying more for its pipeline. Counterweight: sector rallies can cool if deal flow slows.

    Explains the broad demand backdrop pushing innovative drug stocks, including Innovent, higher.

Latest
▲4

Innovent adds Daiichi deal and weekly GLP-1 filing as sector re-rates

  • World-first weekly oral GLP-1 enters clinic Innovent's IBI3042 became the first small-molecule weekly oral GLP-1 to reach clinical stage, with China's drug regulator accepting the filing. A once-weekly pill would be easier for patients than injections, so success could open a large obesity and diabetes market and lift long-term sales hopes.

    New pipeline milestone that expands Innovent's biggest growth opportunity beyond current products.

  • Wins China rights to Daiichi Sankyo's Vanflyta Innovent secured exclusive China commercialization rights for Vanflyta, a leukemia drug approved in June 2026, while Daiichi Sankyo handles development and supply. This adds a near-term oncology product to sell through Innovent's existing hospital network, lifting revenue without big new research spending.

    A concrete new commercial deal that adds revenue and shows Innovent's partnering strength.

  • First-half product revenue up over 55% Innovent's first-half product revenue topped 8.2 billion yuan, up more than 55% year on year, reported alongside strong results from BeiGene and RemeGen. Faster product sales show its medicines are being adopted widely, which supports profit growth and gives the stock a fundamental reason to rise.

    Actual reported sales growth is the core evidence behind the share price move.

  • Sector re-rating on record licensing and Moderna data Chinese drug licensing deals hit about $99.7 billion in the first half, roughly double all of 2024, and Moderna's cancer vaccine success lifted biotech shares globally. Innovent landed billion-dollar overseas deals, so investors are paying more for its pipeline. Counterweight: sector rallies can cool if deal flow slows.

    Explains the broad demand backdrop pushing innovative drug stocks, including Innovent, higher.

July 2026
▲4

Innovent advances novel drugs and expands commercial reach

  • Tri-specific antibody enters Phase 3 Innovent dosed the first patient in a Phase 3 trial of IBI3003 for multiple myeloma. This novel therapy showed strong early results and has FDA Fast Track status. Success could add a major new treatment to Innovent's pipeline, boosting future revenue prospects.

    This is a new clinical milestone that could lead to a new drug approval and revenue stream.

  • Ollin raises $330M for eye drug Innovent's partner Ollin Biosciences raised $330 million to fund global Phase 3 trials of an eye drug discovered by Innovent. The trials will include China and South Korea. This validates Innovent's research and could bring milestone payments and royalties.

    This is new partnership progress that could generate future revenue for Innovent.

  • Gains China rights to Verzenio Eli Lilly handed over sole commercialization rights for breast cancer drug Verzenio in mainland China to Innovent. The drug had about $221 million in sales last year. This expands Innovent's oncology portfolio and adds immediate revenue.

    This is a new commercial agreement that directly boosts Innovent's product sales.

  • Licenses anti-CD40L antibody to Spero Innovent licensed IBI355, an autoimmune disease antibody, to Spero Therapeutics outside Greater China in a deal worth up to $1.1 billion. Innovent gets an upfront payment and potential milestones and royalties, while keeping China rights.

    This is a new out-licensing deal that provides cash and validates Innovent's pipeline.

▲4

Innovent advances novel drugs and expands commercial reach

  • Tri-specific antibody enters Phase 3 Innovent dosed the first patient in a Phase 3 trial of IBI3003 for multiple myeloma. This novel therapy showed strong early results and has FDA Fast Track status. Success could add a major new treatment to Innovent's pipeline, boosting future revenue prospects.

    This is a new clinical milestone that could lead to a new drug approval and revenue stream.

  • Ollin raises $330M for eye drug Innovent's partner Ollin Biosciences raised $330 million to fund global Phase 3 trials of an eye drug discovered by Innovent. The trials will include China and South Korea. This validates Innovent's research and could bring milestone payments and royalties.

    This is new partnership progress that could generate future revenue for Innovent.

  • Gains China rights to Verzenio Eli Lilly handed over sole commercialization rights for breast cancer drug Verzenio in mainland China to Innovent. The drug had about $221 million in sales last year. This expands Innovent's oncology portfolio and adds immediate revenue.

    This is a new commercial agreement that directly boosts Innovent's product sales.

  • Licenses anti-CD40L antibody to Spero Innovent licensed IBI355, an autoimmune disease antibody, to Spero Therapeutics outside Greater China in a deal worth up to $1.1 billion. Innovent gets an upfront payment and potential milestones and royalties, while keeping China rights.

    This is a new out-licensing deal that provides cash and validates Innovent's pipeline.

Amgen Inc (AMGN)

Q3 2026
▲2▼2

Amgen Q3: Pelacarsen Blow Sinks Shares, Recalls and Rival Threats Weigh

  • Pelacarsen failure casts doubt on Amgen's olpasiran Novartis' heart drug pelacarsen failed, and because Amgen's similar olpasiran works the same way, investors feared it could fail too. Shares fell about 10% and BMO downgraded the stock.

    This was the single most severe event of the quarter, directly sinking the share price.

  • Court blocks Colorado's 70% Enbrel price cap A court blocked Colorado's 70% price cap on Enbrel, reducing regulatory risk for Amgen's biggest drug. This removes a threat that could have slashed revenue from a key product.

    A major legal win that eased a key overhang on the stock.

  • Q2 beat and raised guidance, key products grow 26% Amgen's Q2 earnings and revenue beat estimates, and the company raised its full-year guidance. Six key products grew 26%, showing the new drug lineup is driving growth.

    Strong financial results and raised outlook support the stock.

  • Recalls, competition, pipeline setback, cyberattack Corlanor and Sensipar recalls raised quality concerns. Merck's cheaper oral PCSK9 threatens Repatha, Sotyktu may erode Otezla, AMG 513 was discontinued, and a cyberattack triggered lawsuits.

    Multiple negative events that weighed on sentiment and future growth prospects.

September 2026
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

Latest
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

August 2026
▲2▼2

Amgen beats Q2, raises guidance, but obesity setback and cyberattack weigh

  • Q2 earnings beat and guidance raise Amgen reported Q2 adjusted EPS of $6.29 and revenue of $10.05B, beating estimates, and raised its 2026 guidance. Six key growth products grew 26%, reducing reliance on older drugs.

    This is a new positive fundamental development that directly supports the stock.

  • Repatha and Tezspire clinical wins Repatha cut death risk by 20% in a major heart trial, and Tezspire met all goals in an eosinophilic esophagitis study. These results lifted shares to a 52-week high and prompted analyst target hikes.

    New clinical data and analyst reactions are key drivers of the stock's move this period.

  • Obesity drug AMG 513 discontinued Amgen discontinued its obesity drug AMG 513, leaving MariTide trailing Eli Lilly and Novo Nordisk in the lucrative obesity market. This raises concerns about Amgen's competitive position.

    This is a new negative event that affects future growth prospects.

  • Cyberattack and drug-price pressure A July cyberattack exposed patient and proprietary data, triggering a class action investigation. Also, a looming US drug-price agreement with mid-sized biotechs could pressure Medicaid revenue.

    These are new risk factors that emerged during the period and could weigh on the stock.

▲3▼1

Amgen Hits 52-Week High on Q2 Beat, Repatha and Tezspire Wins

  • Repatha Cuts Death Risk 20% in Major Heart Trial Amgen's Repatha reduced death risk by 20% in high-risk heart patients in the VESALIUS-CV trial, a major win for its biggest growth drug. This strengthens the case for wider use and future sales, supporting a higher stock price.

    This is a new, high-impact clinical win that directly boosts confidence in Amgen's key growth driver.

  • Tezspire Meets All Goals in Eosinophilic Esophagitis Trial Amgen and AstraZeneca's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, a chronic throat condition with few good treatments. This opens a new market and adds to Tezspire's growth story, lifting investor optimism.

    New positive trial results expand a key product's potential, a fresh catalyst for the stock.

  • US Drug Price Agreement with Mid-Sized Biotechs Looms The Trump administration is expected to announce a drug price agreement with mid-sized biotech firms, and Amgen was among companies urged to cut US prices. If Amgen is included, lower Medicaid prices could pressure revenue and weigh on the stock.

    This is a new regulatory risk that could directly affect Amgen's pricing and profits.

  • Analyst Fair Value and Price Targets Raised After Q2 Beat Following Amgen's strong Q2 results, analysts raised their fair value estimate to about $372 and several price targets into the $450 range, citing broad franchise strength. Higher targets can pull the stock up as investors adjust expectations.

    This is a new analyst reaction that reflects upgraded expectations and can influence the stock price.

▲2▼2

Amgen Q2 Beat and Guidance Raise Outweigh Data Breach and Obesity Setback

  • Q2 earnings beat and raised 2026 guidance Amgen reported Q2 adjusted EPS of $6.29, well above the $5.62 consensus, and revenue of $10.05 billion, up 10% and ahead of forecasts. Management raised full-year revenue and EPS guidance, signaling confidence in the business. This directly boosts the stock as investors see stronger profits ahead.

    This is the main new positive event that drove the stock up over 5% this period.

  • Key growth drivers show strong momentum Six key products, including Repatha, Evenity, Uplizna, and Imdelltra, grew 26% year-over-year and now make up nearly 70% of product sales. This reduces reliance on older drugs like Enbrel and Otezla, which are facing competition. The shift supports future revenue growth and lifts investor confidence.

    It explains the underlying strength behind the earnings beat and why the stock rose.

  • Cybersecurity breach and class action investigation Amgen disclosed a July cyberattack where sensitive patient and proprietary data was stolen. A law firm has launched a class action investigation. This creates legal and reputational risk, which could weigh on the stock, though Amgen says operations are not materially affected.

    It is a new negative event that could pressure the stock and is important for a balanced view.

  • Obesity drug AMG 513 discontinued; MariTide faces tough competition Amgen ended development of early-stage obesity drug AMG 513, leaving MariTide as its only obesity candidate. MariTide's weight-loss data trails Eli Lilly's and Novo Nordisk's drugs, and switching patients may be hard. This raises doubts about Amgen's ability to compete in the lucrative obesity market.

    It is a new setback that could limit future growth and is a key counterweight to the positive earnings.

July 2026
▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

Q2 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

June 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

© 2026 MarketIVWhy